title: Pulmonary epithelioid haemangioendothelioma studies in vitro and in vivo: new diagnostic and treatment methods.
abstract: BACKGROUND
  Pulmonary epithelioid haemangioendothelioma is a rare endothelial tumour without standard treatment. For this reason, our aim is to present contemporary research outlining new therapeutic possibilities; thus in vitro and in vivo methods were combined.
  
  
  METHODS
  Pulmonary epithelioid haemangioendothelioma was diagnosed in a 49-year-old female patient. A bronchial excision was obtained from a parenchymal lesion, and the excised sample was manipulated with in vitro-standardized experiments to support the diagnostic and therapeutic procedures.
  
  
  RESULTS
  according to in vitro examination of tumour pulmonum and metastases from bone, carboplatin, docetaxel and pharmarubicin was the most effecient treatment modality.
  
  
  CONCLUSIONS
  Currently, pulmonary epithelioid haemangioendothelioma does not have any standard treatment; the most efficient therapeutic regimen was gradually developed by combining in vitro and in vivo methods, which proved to be an efficient therapeutic modality hitherto.
authors: Department of Pulmonology, Faculty of Medicine, University of Szeged, Alkotmány street 36, H-6772, Deszk, Hungary. palfoldi@deszkikorhaz.hu
authors: Regina
authors: R
authors: Pálföldi
authors: Marianna
authors: M
authors: Radács
authors: Edit
authors: E
authors: Csada
authors: Zsolt
authors: Z
authors: Molnár
authors: Sándor
authors: S
authors: Pintér
authors: László
authors: L
authors: Tiszlavicz
authors: József
authors: J
authors: Molnár
authors: Zsuzsanna
authors: Z
authors: Valkusz
authors: Attila
authors: A
authors: Somfay
authors: Márta
authors: M
authors: Gálfi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D016190:Carboplatin / Q000494:pharmacology / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D018450:Disease Progression; D000077143:Docetaxel; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D018323:Hemangioendothelioma, Epithelioid / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D057285:Precision Medicine; D013902:Radiography, Thoracic; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D016190:Carboplatin